Irene A. Retmana

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure.

ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: February 28, 2024

Development and validation of an LC-MS/MS method for the quantification of KRASG12C inhibitor opnurasib in several mouse matrices and its application in a pharmacokinetic mouse study.

Development and validation of an LC-MS/MS method for the quantification of KRASG12C inhibitor opnurasib in several mouse matrices and its application in a pharmacokinetic mouse study.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Published: September 25, 2023

Validated LC-MS/MS method for simultaneous quantification of KRASG12C inhibitor sotorasib and its major circulating metabolite (M24) in mouse matrices and its application in a mouse pharmacokinetic study.

Validated LC-MS/MS method for simultaneous quantification of KRASG12C inhibitor sotorasib and its major circulating metabolite (M24) in mouse matrices and its application in a mouse pharmacokinetic study.

Journal: Journal of pharmaceutical and biomedical analysis

Published: April 24, 2023

Pharmacokinetics of the KRASG12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c.

Pharmacokinetics of the KRASG12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: March 29, 2023

Development and validation of an HPLC-MS/MS method to quantify the KRAS inhibitor adagrasib in mouse plasma and tissue-related matrices.

Development and validation of an HPLC-MS/MS method to quantify the KRAS inhibitor adagrasib in mouse plasma and tissue-related matrices.

Journal: Biomedical chromatography : BMC

Published: December 08, 2022

Corrigendum to "Variability of in vivo potency tests of Diphtheria, Tetanus and acellular Pertussis (DTaP) vaccines" [Vaccine 39(18) (2021) 2506-2516].

Corrigendum to "Variability of in vivo potency tests of Diphtheria, Tetanus and acellular Pertussis (DTaP) vaccines" [Vaccine 39(18) (2021) 2506-2516].

Journal: Vaccine

Published: April 26, 2022

ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability.

ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability.

Journal: Pharmacological research

Published: December 08, 2021

Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Published: March 03, 2021

Variability of in vivo potency tests of Diphtheria, Tetanus and acellular Pertussis (DTaP) vaccines.

Variability of in vivo potency tests of Diphtheria, Tetanus and acellular Pertussis (DTaP) vaccines.

Journal: Vaccine

Published: November 14, 2020

Chromatographic bioanalytical assays for targeted covalent kinase inhibitors and their metabolites.

Chromatographic bioanalytical assays for targeted covalent kinase inhibitors and their metabolites.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Published: September 24, 2020

P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.

P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.

Journal: International journal of pharmaceutics

Published: September 21, 2018

Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction.

Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Published: April 18, 2017

Showing 1-12 of 12

Last Updated: 09/26/2026